港股异动 | 复宏汉霖(02696)午后涨超4% 近日H药汉斯状®日本一线治疗小细胞肺癌桥接试验完成入组

智通财经05-18

智通财经APP获悉，复宏汉霖(02696)午后涨超4%，截至发稿，涨3.19%，报69.65港元，成交额3725.2万港元。

消息面上，近日，据复宏汉霖官微消息，公司宣布，其自主研发的创新型抗PD-1单抗H药汉斯状^®(斯鲁利单抗，欧洲商品名：Hetronifly^®)联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)适应症的日本桥接试验(NCT06812260)已顺利完成全部受试者入组。该桥接试验旨在评估H药联合化疗一线治疗ES-SCLC在日本患者中的疗效及安全性，由关西医科大学附属医院Takayasu Kurata教授担任牵头主要研究者。

NCT06812260以及支持ES-SCLC在中国和欧洲等地获批的ASTRUM-005研究结果，将共同构成支持H药在日本市场注册申报的关键临床数据，并计划携手日本合作伙伴卫材于其2026财年期间递交上市申请。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2636272044?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-18 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636272044","market":"sh","top_or_hot":-1,"title":"港股异动 | 复宏汉霖(02696)午后涨超4% 近日H药汉斯状®日本一线治疗小细胞肺癌桥接试验完成入组","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696)午后涨超4%，截至发稿，涨3.19%，报69.65港元，成交额3725.2万港元。</p><p>消息面上，近日，据复宏汉霖官微消息，公司宣布，其自主研发的创新型抗PD-1单抗H药汉斯状<sup>®</sup>(斯鲁利单抗，欧洲商品名：Hetronifly<sup>®</sup>)联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)适应症的日本桥接试验(NCT06812260)已顺利完成全部受试者入组。该桥接试验旨在评估H药联合化疗一线治疗ES-SCLC在日本患者中的疗效及安全性，由关西医科大学附属医院Takayasu Kurata教授担任牵头主要研究者。</p><p>NCT06812260以及支持ES-SCLC在中国和欧洲等地获批的ASTRUM-005研究结果，将共同构成支持H药在日本市场注册申报的关键临床数据，并计划携手日本合作伙伴卫材于其2026财年期间递交上市申请。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 复宏汉霖(02696)午后涨超4% 近日H药汉斯状®日本一线治疗小细胞肺癌桥接试验完成入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 复宏汉霖(02696)午后涨超4% 近日H药汉斯状®日本一线治疗小细胞肺癌桥接试验完成入组\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696)午后涨超4%，截至发稿，涨3.19%，报69.65港元，成交额3725.2万港元。</p><p>消息面上，近日，据复宏汉霖官微消息，公司宣布，其自主研发的创新型抗PD-1单抗H药汉斯状<sup>®</sup>(斯鲁利单抗，欧洲商品名：Hetronifly<sup>®</sup>)联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)适应症的日本桥接试验(NCT06812260)已顺利完成全部受试者入组。该桥接试验旨在评估H药联合化疗一线治疗ES-SCLC在日本患者中的疗效及安全性，由关西医科大学附属医院Takayasu Kurata教授担任牵头主要研究者。</p><p>NCT06812260以及支持ES-SCLC在中国和欧洲等地获批的ASTRUM-005研究结果，将共同构成支持H药在日本市场注册申报的关键临床数据，并计划携手日本合作伙伴卫材于其2026财年期间递交上市申请。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1442808.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320223.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1442808.html","article_id":"2636272044","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636272044","pubTimestamp":1779084010,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，复宏汉霖午后涨超4%，截至发稿，涨3.19%，报69.65港元，成交额3725.2万港元。消息面上，近日，据复宏汉霖官微消息，公司宣布，其自主研发的创新型抗PD-1单抗H药汉斯状联合化疗一线治疗广泛期小细胞肺癌适应症的日本桥接试验已顺利完成全部受试者入组。NCT06812260以及支持ES-SCLC在中国和欧洲等地获批的ASTRUM-005研究结果，将共同构成支持H药在日本市场注册申报的关键临床数据，并计划携手日本合作伙伴卫材于其2026财年期间递交上市申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","VXUS":"国际股票ETF-Vanguard","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","02696":"复宏汉霖","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"Hong Kong stock changes | Fuhong Henlius (02696) rose more than 4% in the afternoon. Recently, H drug Hans Zhuang ® Japan's first-line treatment of small cell lung cancer bridging trial completed enrollment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"02696":1.5},"content_text":"智通财经APP获悉，复宏汉霖(02696)午后涨超4%，截至发稿，涨3.19%，报69.65港元，成交额3725.2万港元。消息面上，近日，据复宏汉霖官微消息，公司宣布，其自主研发的创新型抗PD-1单抗H药汉斯状®(斯鲁利单抗，欧洲商品名：Hetronifly®)联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)适应症的日本桥接试验(NCT06812260)已顺利完成全部受试者入组。该桥接试验旨在评估H药联合化疗一线治疗ES-SCLC在日本患者中的疗效及安全性，由关西医科大学附属医院Takayasu Kurata教授担任牵头主要研究者。NCT06812260以及支持ES-SCLC在中国和欧洲等地获批的ASTRUM-005研究结果，将共同构成支持H药在日本市场注册申报的关键临床数据，并计划携手日本合作伙伴卫材于其2026财年期间递交上市申请。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636272044","isCrawlerRequest":true}